MEASE, P. J.; CHOHAN, S.; GARCIA FRUCTUOSO, F. J.; GOTTLIEB, A. B.; CHOU, R. C.; MENDELSOHN, A. M.; LUGGEN, M. E. Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 4, n. 5, p. s43, 2020. DOI: 10.25251/skin.4.supp.43. Disponível em: https://jofskin.org/index.php/skin/article/view/992. Acesso em: 22 jul. 2024.